This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rex, J. H.
Right arrow Articles by Rinaldi, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rex, J. H.
Right arrow Articles by Rinaldi, M. G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, Apr 1996, 816-817, Vol 34, No. 4
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole

JH Rex, MA Pfaller, M Lancaster, FC Odds, A Bolmstrom and MG Rinaldi
Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA. jrex@heart.med.uth.tmc.edu

Ketoconazole and itraconazole were tested in a multilaboratory study to establish quality control (QC) guidelines for yeast antifungal susceptibility testing. Two isolates that had been previously identified as QC isolates for amphotericin B, fluconazole, and flucytosine (Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258) were tested in accordance with the National Committee for Clinical Laboratory Standards M27-P guidelines. Each isolate was tested 20 times with the two antifungal agents in the five laboratories by using a lot of RPMI 1640 unique to each laboratory as well as a lot common to all five laboratories, thus generating 200 MICs per drug per organism. Overall, 96 to 99% of the MICs for each drug fell within the desired 3-log2 dilution range (mode +/- 1 log2 dilution). By using these data, 3-log2 dilution QC ranges encompassing 98% of the observed MICs for three of the organism-drug combinations and 94% of the observed MICs for the fourth combination were established. These QC ranges are 0.064 to 0.25 micrograms/ml for both ketoconazole and itraconazole against C. parapsilosis ATCC 22019 and 0.125 to 0.5 micrograms/ml for both ketoconazole and itraconazole against C. krusei ATCC 6258.


This article has been cited by other articles:

  • Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., Min, F., Zhao, W., Zhuo, Y., You, J., Song, Y., Yu, Z., Liu, Z., Yang, K., Gao, H., Dai, H., Zhang, X., Wang, J., Fu, C., Pei, G., Liu, J., Zhang, S., Goodfellow, M., Jiang, Y., Kuai, J., Zhou, G., Chen, X. (2007). High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl. Acad. Sci. USA 104: 4606-4611 [Abstract] [Full Text]  
  • Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., Mangino, J. E., Lee, J. (2003). Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother. 47: 3149-3154 [Abstract] [Full Text]  
  • Vargas, K., Messer, S. A., Pfaller, M., Lockhart, S. R., Stapleton, J. T., Hellstein, J., Soll, D. R. (2000). Elevated Phenotypic Switching and Drug Resistance of Candida albicans from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode. J. Clin. Microbiol. 38: 3595-3607 [Abstract] [Full Text]  
  • Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., Rinaldi, M. G. (2000). Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents. J. Clin. Microbiol. 38: 3457-3459 [Abstract] [Full Text]  
  • Favre, B., Didmon, M., Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14{alpha}-demethylase contribute to azole resistance in Candida albicans. Microbiology 145: 2715-2725 [Abstract] [Full Text]  
  • Martin-Mazuelos, E., Gutierrez, M. J., Aller, A. I., Bernal, S., Martinez, M. A., Montero, O., Quindos, G. (1999). A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.. J Antimicrob Chemother 43: 477-481 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Graybill, J. R., Montalbo, E., Kirkpatrick, W. R., Luther, M. F., Revankar, S. G., Patterson, T. F. (1998). Fluconazole versus Candida albicans: A Complex Relationship. Antimicrob. Agents Chemother. 42: 2938-2942 [Abstract] [Full Text]  
  • White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  
  • Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., Anaissie, E. J. (1998). Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis. Antimicrob. Agents Chemother. 42: 129-134 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»